Physician profile
David Cantrell
NPI 1467425124
$7,907.40
in general payments reported to CMS, 2019-2025
45 companies · $1,207 in 2025
The $1,207 reported for 2025 was more than what 87% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,952 · 2020: $1,242 · 2021: $672 · 2022: $581 · 2023: $911 · 2024: $1,343 · 2025: $1,207.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,461.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,461.41 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $1,143.49 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Amgen INC. | $843.63 | 2019-2025 | Evenity, Prolia, Repatha |
| Abbvie INC. | $792.10 | 2019-2025 | Vraylar, Ubrelvy |
| Astrazeneca Pharmaceuticals Lp | $642.61 | 2019-2024 | Farxiga, Airsupra, Breztri |
| Pfizer INC. | $526.55 | 2019-2025 | |
| Astellas Pharma US INC | $427.96 | 2019-2025 | Veozah |
| Sanofi-Aventis U.S. LLC | $409.97 | 2019-2025 | |
| Lilly USA, LLC | $298.64 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Glaxosmithkline, LLC. | $270.31 | 2019-2025 | Shingrix, Arexvy, Trelegy Ellipta |
| Amarin Pharma, INC. | $236.09 | 2019-2021 | |
| Novartis Pharmaceuticals Corporation | $216.01 | 2019-2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $205.20 | 2019-2025 | Xifaxan |
| Takeda Pharmaceuticals U.S.A., INC. | $145.48 | 2019-2022 | |
| Abbott Laboratories | $140.94 | 2019-2025 | Freestyle Libre 3 |
| Dexcom, INC. | $133.94 | 2022-2025 | Dexcom G6 Transmitter |
Show all 45 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, INC. | $127.96 | 2019-2024 | |
| Sumitomo Pharma America, INC. | $116.96 | 2023-2025 | Gemtesa |
| Allergan, INC. | $112.24 | 2019-2020 | |
| Janssen Pharmaceuticals, INC | $104.53 | 2019-2020 | |
| Exact Sciences Corporation | $96.37 | 2023-2025 | Cologuard Collection Kit |
| Merck Sharp & Dohme LLC | $84.93 | 2019-2024 | Vaqta, Gardasil, Gardasil 9 |
| Bayer Healthcare Pharmaceuticals INC. | $78.29 | 2022-2025 | |
| Eisai INC. | $71.30 | 2020-2021 | |
| Xeris Pharmaceuticals, INC. | $69.49 | 2022-2024 | Gvoke Hypopen |
| Sanofi Pasteur INC. | $65.00 | 2020-2025 | |
| Esperion Therapeutics, INC. | $59.36 | 2020-2025 | Nexletol |
| Antares Pharma, INC. | $59.36 | 2022-2023 | Xyosted, Tlando, Nocdurna |
| Ironwood Pharmaceuticals, INC | $44.20 | 2019-2020 | |
| Gilead Sciences, INC. | $34.03 | 2020-2025 | |
| Boston Scientific Corporation | $33.78 | 2025 | General - Pain Management |
| Phathom Pharmaceuticals, INC. | $33.74 | 2024-2025 | Voquezna |
| Radius Health, INC. | $33.45 | 2020-2021 | |
| Kowa Pharmaceuticals America, INC. | $26.57 | 2020 | |
| Abiomed | $26.49 | 2025 | |
| Ironshore Pharmaceuticals INC. | $24.28 | 2019 | |
| Aytu Biopharma, INC. | $22.83 | 2020 | |
| Hikma Pharmaceuticals USA | $20.20 | 2019 | |
| Pulmonx Corporation | $20.00 | 2024 | Chartis Catheter, Zephyr Endobronchial Valve, Pulmonx Chartis Tablet Console |
| Biogen, INC. | $19.93 | 2025 | Leqembi |
| Shield Therapeutics INC | $18.49 | 2022 | |
| Biohaven Pharmaceuticals, INC. | $16.21 | 2021 | |
| Becton, Dickinson and Company | $15.74 | 2022 | |
| Amneal Pharmaceuticals LLC | $15.57 | 2019 | |
| Shire North American Group INC | $12.21 | 2019 | |
| Teva Pharmaceuticals USA, INC. | $10.97 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw David Cantrell listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.